Cosentyx® Intravenous (secukinumab)

Intravenous Cosentyx (secukinumab) is covered for adults (≥18) with active psoriatic arthritis, active ankylosing spondylitis, or active non‑radiographic axial spondyloarthritis with objective signs of inflammation (e.g., elevated CRP or MRI sacroiliitis); pediatric use and non‑radiographic disease without objective inflammation are excluded. Coverage requires specialist prescribing/consultation (rheumatologist for AS and non‑radiographic axial SpA; rheumatologist or dermatologist for PsA), documentation of diagnosis and weight‑based IV dosing (loading and maintenance per policy, max 300 mg/infusion), 12‑month approval, and reauthorization only after ≥6 months on therapy with documented clinical benefit by objective measures or symptom improvement.

"Adult patients with active psoriatic arthritis;"

Sign up to see full coverage criteria, indications, and limitations.